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Abstract
Background: The neurotrophic hypothesis postulates that mood disorders such as bipolar disorder (BD) are associated
with a lower expression of brain-derived neurotrophic factor (BDNF). However, its role in peripheral blood as a biomarker
of disease activity and of stage for BD, transcending pathophysiology, is still disputed. In the last few years an increasing
number of clinical studies assessing BDNF in serum and plasma have been published. Therefore, it is now possible to
analyse the association between BDNF levels and the severity of affective symptoms in BD as well as the effects of acute
drug treatment of mood episodes on BDNF levels.
Methods: We conducted a systematic review and meta-analysis of all studies on serum and plasma BDNF levels in
bipolar disorder.
Results: Through a series of meta-analyses including a total of 52 studies with 6,481 participants, we show
that, compared to healthy controls, peripheral BDNF levels are reduced to the same extent in manic (Hedges’ g = −0.57,
P = 0.010) and depressive (Hedges’ g = −0.93, P = 0.001) episodes, while BDNF levels are not significantly altered in
euthymia. In meta-regression analyses, BDNF levels additionally negatively correlate with the severity of both manic and
depressive symptoms. We found no evidence for a significant impact of illness duration on BDNF levels. In addition, in
plasma, but not serum, peripheral BDNF levels increase after the successful treatment of an acute mania episode, but not
of a depressive one.
Conclusions: In summary, our data suggest that peripheral BDNF levels, more clearly in plasma than in serum, is a
potential biomarker of disease activity in BD, but not a biomarker of stage. We suggest that peripheral BDNF may, in
future, be used as a part of a blood protein composite measure to assess disease activity in BD.
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Background
The quest for useful biomarkers in bipolar disorder (BD)
is gaining momentum. One of the most extensively in-
vestigated proteins in BD is brain-derived neurotrophic
factor (BDNF). It was first isolated [1] after the seren-
dipitous discovery of the nerve growth factor in 1952
[2]. The neurotrophic hypothesis was originally formulated
in 1997 by Duman, Heninger, and Nestler [3], and charac-
terizes major depressive disorder as being secondary to ab-
errant neurogenesis in brain regions that regulate emotion
and memory, with aberrant neurogenesis associated with
lower expression of BDNF. BDNF rapidly became a popu-
lar research topic, with the first study of BDNF levels in
peripheral blood conducted in 2002 by Karege et al. [4].
Science historians have often noticed that, at any given
time, scholars in a particular field tend to share basic
* Correspondence: brisasf@gmail.com; andrefc7@terra.com.br
Brisa S. Fernandes and Marc L. Molendijk equal contributions as first authors.
Michael Berk and André F. Carvalho equal contributions as senior authors.
1Deakin University, IMPACT Strategic Research Centre, School of Medicine,
Geelong, Australia
5Translational Psychiatry Research Group and Department of Clinical
Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE,
Brazil
Full list of author information is available at the end of the article
© 2015 Fernandes et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fernandes et al. BMC Medicine  (2015) 13:289 
DOI 10.1186/s12916-015-0529-7
assumptions about their subject [5]; this quickly turned
out to be the case for the neurotrophic hypothesis, which,
since its original formulation, was first expanded to in-
clude schizophrenia by Toyooka in 2002 [6]. BD followed,
with Laske et al. [7], in 2005, first showing decreased
serum BDNF levels in mania, and Palomino et al. [8], in
2006, showing that peripheral BDNF increased after treat-
ment of acute mania.
Research on peripheral BDNF was originally driven by
the aim of better understanding the pathophysiology of
mood disorders; however, in the last few years, BDNF
has been attracting attention as a potential biomarker
capable of advancing the elusive field of personalised
medicine in psychiatry [9–11]. BDNF was an obvious
choice, since its levels in peripheral blood can be assessed
easily and relatively non-invasively through venepuncture,
and BDNF levels in serum and plasma are highly corre-
lated with BDNF levels in the central nervous system, as
BDNF freely crosses the blood–brain barrier [4, 12, 13]. In
BD, several studies have been conducted with discrepant
results. Most of these studies have suggested peripheral
BDNF as a state-marker in BD, with decreased levels in
mania and depression returning to normal in euthymia,
and also being correlated with severity of mania and
depression [14, 15]. Based on that, we earlier proposed
peripheral BDNF as a potential biomarker of disease ac-
tivity in BD [14, 16, 17], and presented preliminary data
suggesting that BDNF could play a role as a biomarker
capable of supporting the clinical diagnosis of BD. Bipolar
disorder has been conceptualized as a neuroprogressive
illness, in which recurring affective episodes may lead to
cognitive deterioration and/or refractoriness, although it is
acknowledged that some cognitive and functional prob-
lems are present to a lesser extent since the first bipolar
episode [18, 19]. It has been suggested that BDNF levels
may reflect neuroprogressive changes in BD, and thus
may hold promise as a stage biomarker [11, 14, 20].
The inconsistent findings regarding peripheral BDNF
levels in BD might be caused by heterogeneous patient
populations or by small sample sizes lacking statistical
power. Meta-analysis is a recognized technique used to
resolve discrepancies between studies. It is a quantitative
method that combines results from independent studies
to increase statistical power in order to derive more
solid conclusions [21, 22]. In addition, meta-regression
may be used to evaluate confounders and discrepancies
among different studies [23, 24]. At the moment, five
meta-analyses have been conducted on the topic of per-
ipheral BDNF levels in BD with conflicting results. The
first three [14–16] showed decreased BDNF during acute
mood states, and the last two showed BDNF levels de-
creased during depression but not in mania [25, 26].
The largest one to date included 35 studies; however,
this is a rapidly evolving field, and now 52 studies are
available. Thus, there is a sounder basis to definitively
analyse the relationship between BDNF levels, mood
states, severity of manic and depressive symptoms, and
treatment response, including the pivotal role of periph-
eral BDNF levels as a biomarker in BD. Particularly,
from a biomarker development perspective, it is im-
portant to analyse which compartment would be more
adequate for BDNF measurement, plasma or serum,
and if use of psychiatric drugs might influence BDNF
as a biomarker.
Therefore, the aims of this large, collaborative meta-
analysis were to verify the properties of peripheral BDNF
levels as a biomarker of disease activity and of stage in
BD. For this, we ascertained if peripheral BDNF levels
are indeed decreased in BD across the different mood
states and whether its levels are associated with severity
of manic and depressive symptoms, thus being a state-
marker and, as a result, behaving as a biomarker of dis-
ease activity. To determine if peripheral BDNF levels
could be a stage biomarker in BD, we examined if its
levels are associated with duration of illness. In addition,
we aimed to assess whether BDNF levels change fol-
lowing pharmacological treatment of an acute mood
episode. With this in mind, we performed a series of
meta-analysis of all cross-sectional studies of peripheral
BDNF levels in BD compared to healthy subjects, and also
evaluated longitudinal studies on BDNF levels before and
after prescription of psychiatric medication, exploring its
relations to manic and depressive symptoms and response
to treatment. Based on results from the previous meta-
analyses, we expected high levels of between-study hetero-
geneity. Thus, we aimed to explore potential moderators
of the differences in BDNF levels among individuals with
BD compared to healthy controls, as well as longitudinally
after pharmacological treatment. We also aimed to group
results according to sample source (plasma, serum, or
whole blood) to determine which one would be more
appropriate for assessment of BDNF levels, and also to
search for differences of efficiency in effect sizes and
heterogeneity. All these aspirations are now possible
due to the large amount of data currently available and
will help to clarify the role of peripheral BDNF as a bio-
marker in BD.
Methods
We performed four between-group meta-analyses of
peripheral levels of BDNF in subjects with BD accord-
ing to mood state: (1) in subjects with BD in mania
compared to healthy controls; (2) in subjects with BD
in depression compared to healthy controls; (3) in sub-
jects with BD in a mixed episode compared to healthy
controls; and (4) in subjects with BD in euthymia com-
pared to healthy controls. We also conducted the following
two within-group meta-analyses: (1) a meta-analysis of
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peripheral BDNF levels changes in participants with BD
in a manic episode at baseline and after pharmaco-
logical treatment, and (2) a meta-analysis of peripheral
BDNF levels in participants with BD in a depressive
episode at baseline and after pharmacological treat-
ment. The protocol developed for this meta-analytic re-
view adhered to the recommendations of the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [27]. Each element of
the literature search, selection of eligible studies and
data extraction were performed by at least two authors
(CMGSL, TLR, JCS, BSF, and MLM). Disagreements were
resolved through consensus. Following harmonization of
the data extraction process, three authors (AFC, BSF, and
PMGS) checked the extracted data and corrected eventual
inconsistencies.
Search strategy
We conducted a systematic search of all potentially eligible
references (including meeting abstracts) without language
restrictions to avoid language publication bias, using
PubMed/MEDLINE, EMBASE, and PsycINFO comput-
erized databases. One article was published in manda-
rin and was translated by a native mandarin speaker.
The search string used for the electronic database search
was (Bipolar disorder OR mania OR bipolar depression)
AND (BDNF OR brain-derived neurotrophic factor). The
last search was performed in May 31st, 2015. This search
strategy was augmented by tracking the citations of eli-
gible articles in Google Scholar database to identify
additional eligible references.
Study selection
The inclusion criteria were (1) adult individuals with BD
regardless of mood state meeting either International
Classifications of Disease or Diagnostic and Statistical
Manual for Mental Disorders diagnostic criteria; (2)
pairwise comparison with a control group of healthy
volunteers for the between-group meta-analyses, or
longitudinal studies before and after drug treatment for
an acute mood episode for the within-group meta-
analyses; and (3) studies that measured peripheral
BDNF levels in vivo. Exclusion criteria were (1) post
mortem brain studies without information on BDNF
levels in the periphery; (2) case reports; (3) genetic
studies without information on BDNF levels in the per-
iphery; (4) studies that included samples with mixed
psychiatric diagnoses unless data for BD were reported
separately or were obtained after contacting the au-
thors; and (5) preclinical data. The authors consensu-
ally agreed on the final inclusion of references for this
meta-analytic review.
Data extraction
Two reviewers independently extracted data (sample
size, mean and standard deviation) to prevent potential
errors. All variables were extracted by diagnostic status
(euthymic, manic, depressed, or mixed episode). We re-
corded age, sex (% female), and length of illness in years.
We computed scores for manic as well as depressive
symptoms as assessed through standard rating instru-
ments, such as the Young Mania Rating Scale (YMRS)
and the Hamilton Depression Rating Scale (HDRS) [28],
respectively. We also extracted information regarding
sampling (plasma, serum or whole blood), type of assay
(radioimmunoassay or enzyme-linked immunosorbent
assay), and manufacturer of the assay kit. Finally, infor-
mation on age- and sex-matching of BD and control
samples as well as the type of diagnostic interview was
obtained. Subjects with BD were considered drug-free
when they were off psychiatric medication for at least
2 weeks prior to venepuncture. Treatment response for
the within-group meta-analyses was defined as an at
least 50 % reduction in baseline HDRS or YMRS scores
for a depressive or manic episode, respectively.
Discrepancies in data entry were double-checked by
the reviewers with the original published data and a con-
sensus was reached. Authors of meeting abstracts were
contacted by e-mail on at least two different occasions
requesting the provision of data. Furthermore, correspond-
ing authors of included articles were contacted whenever
necessary data were unavailable, and the required informa-
tion was then requested. Whenever multiple reports per-
tained to the same participants, we included only the
largest data set. In the within-group meta-analysis, we
considered only the last post-intervention BDNF meas-
urement. When data were available only in graphs, we
extracted the data according to the procedure explained
by Sistrom et al. [29].
Publication bias
Studies reporting negative results (i.e. statistically non-
significant results) are less likely to be published than
studies with positive results [30, 31]. We estimated the
likelihood of publication bias based on the following as-
sumptions for the existence of small-study effects: (1)
the effect size of the largest study is more conservative
than the pooled effect size of the respective meta-
analysis and (2) a P value of less than 0.1 in the Egger’s
asymmetry test [32] as suggested by Belbasis et al. [33].
The trim-and-fill procedure, which is a validated model
to estimate an effect size (ES) after bias has been taken
into account, was employed when publication bias in the
funnel plots was demonstrated. Finally, the file drawer
statistic (i.e. the Fail-safe N test) was used to quantify
the number of possible negative omitted studies neces-
sary to turn the ES estimate non-significant.
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Statistical analysis
Eligible studies included different assay methods; thus,
standardized mean difference estimates, using Hedges’
adjusted g, which provides a relatively unbiased ES ad-
justed for sample size, were used to estimate differences
in peripheral BDNF levels of individuals with BD com-
pared to healthy controls (in the between-group meta-
analyses) and between baseline and post-treatment
peripheral levels of BDNF (in the within-group meta-
analyses). The 95 % confidence interval (95 % CI) of
the ES was also computed. An ES of 0.2 was regarded
as small, while an ES of 0.5 was considered moderate
and an ES ≥0.8 was considered large.
Heterogeneity across studies was evaluated using the
Cochran Q test, a weighed sum of the squares of the de-
viations in individual study ES estimates from the sum-
mary ES estimate, and a P value of <0.10 was considered
significant (i.e. indicative of heterogeneity). We also cal-
culated the I2 metric [24, 34, 35] as a measure of incon-
sistency across studies; I2 values >50 % were regarded as
indicative of large heterogeneity, while I2 values >75 %
were deemed as an evidence of very large heterogeneity.
The I2 statistic should be interpreted as the proportion
of total variance in study estimates that is due to hetero-
geneity. We also estimated the 95 % CI, which further
accounts for between-study heterogeneity and evaluates
the uncertainty of the effect that would be expected in
new studies investigating the same association [36, 37].
Both measures of heterogeneity (i.e. the Cochran Q test
and the I2 metric) have a limited power to detect hetero-
geneity unless very large data sets are available. Thus, we
pooled ES estimates of individual studies using random
effects, which allows population-level inferences and is
more stringent than fixed-effects models. Random-effects
models have the assumption that a genuine diversity across
study results is present and incorporates a between-study
variance into the calculations [38]. The level of significance
for the effect estimates was set at α = 0.05.
Unrestricted maximum likelihood random-effects meta-
regressions were performed with mean age of participants
with BD, mean age of controls, sex (% female) of controls
and patients, sample size (N), mean baseline YMRS or
HDRS scores, follow-up duration (for within-group meta-
analyses), and differences in baseline and post-treatment
YMRS or HDRS scores (for within-group meta-analyses).
We also performed the following subgroup analyses to
search for potential sources of heterogeneity across
studies: BDNF sampling (plasma versus serum versus
whole blood), medication status (on and off psychiatric
medication), and responders versus non-responders
(for within-group meta-analyses). We also conducted
sensitivity analyses to ascertain whether the summary
ES estimates of our meta-analyses were strongly influenced
by any single study.
Based on the summary ES estimates of each meta-
analysis, we estimated the sample size that would be
required for an individual study to detect this effect
considering a power of 0.8 and an alpha level of 0.05.
These analyses were performed using G*Power 3.1
software [39].
Thereafter, we performed a cumulative meta-analysis,
which addresses the impact of new studies in prior
pooled results. For this analysis, individual data sets were
sorted in chronological order. The earliest available
study was included in the analysis first. At each subse-
quent step of the cumulative meta-analysis, one more
study was included in the analysis, and the summary ES
and 95 % CI were recalculated. The ‘Proteus phenomenon’
refers to the situation in which the first published studies
are often the most biased toward inflated effect sizes (i.e.
the winner’s curse); subsequent replication studies tend to
be less biased toward the extreme, often finding evidence
of smaller effects or even contradicting the findings of
initial studies. Thus, cumulative meta-analyses allow
the appreciation of these phenomena.
We used a previously described test for excess signifi-
cance [40]. Briefly, this test evaluates whether the num-
ber of studies with nominally significant results (i.e. with
P <0.05) among those included in a meta-analysis is too
large based on the power that these data sets have to de-
tect effects at α = 0.05. The power estimate for each data
set was calculated. The sum of the power estimates of
each study provides the expected number of data sets
with nominal statistical significance. As described else-
where, the number of expected positive data sets can be
compared with the observed number of statistically sig-
nificant studies in a meta-analysis through a χ2-based
test. The larger the difference between the observed
number and the expected number, the higher the degree
of excess significance bias.
We employed a Kruskal-Wallis test followed by a
Bonferroni correction to perform a direct comparison
of differences in the magnitude of the ESs of the differ-
ent studies in the different mood states in the between-
group meta-analyses. Results of this analysis are shown
as medians and interquartile range of the ESs in the dif-
ferent mood states. All analyses were conducted with
the Comprehensive Meta-analysis software version 2.0
(Borenstein, NH, USA) and/or the STATA version 13.0
software.
Results
Overall, the six meta-analyses included 6,481 partici-
pants (3,339 cases with BD and 3,142 healthy controls).
We identified 1,041 unique references through elec-
tronic database searches. Of those, 927 were excluded
following title/abstract screening, leaving 114 studies
for full-text review. One study for the between-group
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meta-analysis was excluded because it assessed BDNF
levels in different mood states in rapid cycling subjects
in a longitudinal manner; therefore, the BDNF assessed
was subject to the risk of being influenced by the last
episode [41]. Using the same logic, when a study re-
ported BDNF levels in subjects with BD during mania
or depression and healthy controls in the baseline, and
in euthymia after treatment for an acute mood episode,
we did not consider the BDNF values in euthymia for the
between-group meta-analysis of euthymia compared to
healthy controls.
Fifty-two studies fulfilled our inclusion criteria [7–9,
42–90], 44 for the between-group meta-analyses of BD
versus controls in the different mood states [7–9, 42–50,
52, 53, 55, 57–64, 66, 68–77, 79–87, 90], providing data
on 5,741 participants, of whom 2,599 were subjects with
BD and 3,142 were healthy controls, and 18 studies for
the within-group meta-analyses of BDNF changes after
treatment following an index mood episode [8, 47, 51,
55–57, 59, 61, 64, 65, 67, 71, 78, 84, 87–90], comprising
data on 740 participants. Some studies provided pairwise
comparisons towards more than one meta-analysis. The
PRISMA flowchart of study selection is depicted in
Additional file 1: Figure S1, indicating the 70 studies
excluded and the reasons for this (Additional file 2:
Table S1).
The 44 studies included in the between-group meta-
analyses were published from 2005 to 2015 and varied in
sample size (from 26 to 493). The mean age varied from
21 to 65 years. Nineteen studies explored subjects with
mania [7, 8, 43, 44, 46, 49, 50, 55, 57, 59–61, 64, 70, 76,
84, 85, 87, 90], 15 studies explored subjects with depres-
sion [9, 46, 49, 50, 52, 54, 57, 60, 68, 71, 72, 76, 81, 86, 90],
24 explored subjects in euthymia [42–49, 53, 58, 60, 62, 63,
66, 69, 72–74, 77, 79, 80, 82, 83, 86], and three examined
subjects in a mixed episode [57, 72, 75]. In the studies that
reported on manic subjects, the mean YMRS varied from
22 to 48. Mean HDRS scores varied from 18 to 28 in
studies that reported on depressed subjects. Six studies in
mania provided data regarding drug-free subjects [8, 50,
57, 61, 70, 87] and three regarding drug-free persons with
depression [50, 68, 81]. All studies in euthymia only pro-
vided data for medicated subjects. Regarding the source of
the peripheral BDNF levels, two studies analysed BDNF in
whole blood [64, 87] and 15 in plasma [8, 43–45, 47,
48, 52, 61, 63, 68, 70, 77, 79, 81, 90]. All other studies
considered BDNF in serum. In most of the studies, the
control groups were matched by sex and age to the case
groups.
The general demographic characteristics of the within-
group meta-analyses were similar to the abovementioned
for the between-group meta-analyses. Thirteen studies
analysed changes in BDNF levels following treatment for
an acute manic episode [8, 47, 51, 55, 57, 59, 61, 64, 65,
84, 87, 88, 90] and seven for an acute depressive episode
[56, 57, 67, 71, 78, 89, 90]. The studies were published
from 2006 to 2015 and also varied in sample size (from
6 to 198). The follow-up ranged from 4 to 52 weeks for
an index manic episode, and from 1 to 16 weeks for an
index depressive episode. In mania, the baseline mean
YMRS scores ranged from 11 to 44, and in depression
the mean baseline HDRS scores ranged from 18 to 24.
All studies of an index acute manic episode achieved ag-
gregate response, as defined by a decrease of at least
50 % in mean YMRS scores. The mean changes in the
decreases in YMRS scores ranged from 51 % to 92 % of
the baseline values. The psychiatric medications employed
in the treatment of the manic episode in the studies con-
sidered included lithium, valproate, quetiapine, risperi-
done, and other atypical antipsychotics; most studies used
a combination of these medications. Of the studies con-
sidering BDNF changes with treatment for an index
acute depressive episode, three provided data for re-
sponders [57, 67, 78], as defined by a decrease of at
least 50 % in mean HDRS scores, and four for non-re-
sponders [56, 78, 89, 90]. In general, the mean decreases
in HDRS scores ranged from 10 % to 65 % of the baseline
values. The psychiatric medications employed in the
treatment of the depressive episode in the studies in-
cluded valproate, quetiapine, risperidone, ketamine, a
combination of atypical antipsychotics, and mifepristone.
The majority of the studies assessed BDNF levels
using an ELISA kit. Detailed information regarding
characteristics of the included studies in the between-
group and within-group meta-analyses are provided in
Additional file 2: Tables S2 and S3, respectively.
Peripheral BDNF levels are decreased in BD in mania and
depression in tandem with severity of symptomatology
but not in euthymia
Forty-four studies were included in the between-group
meta-analyses of subjects with BD versus healthy con-
trols in the different mood states [7–9, 42–50, 52, 53,
55, 57–64, 66, 68–77, 79–87, 90], providing data on
5,741 participants, of whom 2,599 were subjects with
BD and 3,142 were healthy controls, which are summa-
rized in Additional file 2: Table S2. Overall, random-
effects between-group meta-analysis showed that per-
ipheral BDNF levels were decreased in subjects with
BD in mania with moderate effect sizes (g = −0.57, 95 %
CI −0.99 to −0.14, P = 0.010, 19 between-group com-
parisons, n = 1,397) and decreased in depression with
large effect sizes (g = −0.93, 95 % CI −1.37 to −0.50, P =
0.001, 15 between-group comparisons, n = 1,074) when
compared to healthy controls. In contrast, there were
no changes in peripheral BDNF levels in euthymia (g =
0.05, 95 % CI −0.13 to 0.24, P = 0.569, 24 between-
group comparisons, n = 3,057; Table 1, Figs. 1 and 2).
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Table 1 Statistics on between-group meta-analyses regarding peripheral brain-derived neurotrophic factor levels in bipolar disorder
Between-group N of pairwise Number of subjects Meta-Analysis Heterogeneity
BD Controls Hedges’ g 95 % CI P value I2 Q P value
Mania
Mania vs. HC – all* 19 605 792 −0.57 −0.99 −0.14 0.010 92.07 239.69 0.001
Mania vs. HC –
drug-naïve or free*
6 175 186 −0.66 −1.14 −0.10 0.020 79.43 29.17 0.001
Mania vs. HC – medicated 14 430 628 −0.54 −1.09 0.00 0.051 92.71 178.41 0.001
Mania vs. HC – serum* 12 288 512 −0.97 −1.41 −0.53 0.001 86.45 81.12 0.001
Mania vs. HC – plasma 6 206 188 −0.03 −0.98 0.95 0.951 94.73 94.94 0.001
Mania vs. HC – plasma
Barbosa excluded*
4 124 92 −0.72 −1.27 −0.17 0.001 70.06 10.02 0.018
Mania vs. HC – whole-
blood
2 144 153 0.12 −0.11 0.35 0.296 N/A N/A N/A
Mania vs. HC –
age-/sex-matched
14 488 551 −0.46 −0.99 0.07 0.073 93.09 202.40 0.001
Mania vs. HC –
not age-/sex-matched*
5 117 241 −0.84 −1.51 −0.18 0.042 86.17 28.90 0.001
Depression
Depression vs. HC – all* 15 352 722 −0.93 −1.37 −0.50 0.001 87.88 107.27 0.001
Depression vs. HC –
drug-naïve or free*
3 47 210 −1.24 −1.88 −0.61 0.001 64.24 5.59 0.061
Depression vs. HC –
medicated*
13 305 534 −0.90 −1.59 −0.55 0.001 88.40 95.51 0.001
Depression vs. HC –
serum*
12 305 519 −0.72 −1.17 −0.27 0.002 87.53 114.67 0.001
Depression vs. HC –
plasma*
3 47 203 −1.94 −3.38 −0.49 0.009 90.25 20.51 0.001
Depression vs. HC –
age-/sex-matched*
10 245 501 −0.81 −1.29 −0.35 0.001 82.26 45.11 0.001
Depression vs. HC – not
age-/sex-matched*
5 107 221 −1.23 −2.30 −0.17 0.023 93.18 58.73 0.001
Depression vs. HC – only
BD type I*
12 219 369 −1.27 −1.80 −0.72 0.001 86.05 71.70 0.001
Euthymia
Euthymia vs. HC – all 24 1598 1459 0.05 −0.13 0.24 0.569 81.19 122.29 0.001
Euthymia vs. HC – serum 16 980 1022 −0.04 −0.16 0.17 0.689 86.67 69.66 0.001
Euthymia vs. HC – plasma 8 618 437 0.26 −0.12 0.65 0.626 86.67 52.51 0.001
Euthymia vs. HC –
age-/sex-matched
16 658 733 0.02 −0.29 0.33 0.894 87.41 119.19 0.001
Euthymia vs. HC – not
age-/sex-matched
7 919 700 −0.06 −0.40 0.26 0.702 88.18 50.75 0.001
Euthymia vs. HC – only
BD type I
16 631 757 0.01 −0.30 0.32 0.319 87.00 115.43 0.001
Euthymia vs. HC – only
BD type II
2 31 48 −0.36 −1.46 0.73 0.729 81.66 5.45 0.001
Mixed State
Mixed state vs. HC – all 3 44 169 0.09 −0.57 0.75 0.787 69.14 6.48 0.039
Moderators between-group N of pairwise Number of subjects Meta-regression Meta-regression
BD Controls Slope 95 % CI P value Intercept Z P value
Mania
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Table 1 Statistics on between-group meta-analyses regarding peripheral brain-derived neurotrophic factor levels in bipolar disorder
(Continued)
Age of BD patients – all* 19 605 792 0.07 0.02 0.13 0.005 −3.41 −3.27 0.001
Age of BD patients –
Barbosa excluded
17 523 696 0.03 −0.03 0.10 0.305 −1.93 −1.54 0.123
Age of controls – all 19 605 792 0.04 −0.01 0.01 0.165 −2.14 −1.85 0.064
Age difference(BD-HC) – all* 19 605 792 0.18 0.05 0.31 0.004 −0.61 −3.15 0.001
Age difference(BD-HC) –
Barbosa excluded
17 523 696 0.08 −0.07 0.24 0.295 −0.74 −3.86 0.001
%Females (Patients)– all 17 579 760 0.01 −0.01 0.04 0.288 −1.33 −1.76 0.076
%Females (HC) – all 17 579 760 0.00 −0.02 0.02 0.811 −0.75 −0.96 0.332
Difference in
%females (BD-HC) – all
17 579 760 0.02 −0.01 0.05 0.250 −0.54 −2.25 0.023
Mean illness duration
(years) – all
13 481 568 0.10 −0.01 0.21 0.070 −1.60 −2.27 0.023
Sample size– all 19 605 792 0.00 −0.00 0.01 0.126 −1.09 −2.68 0.009
YMRS scores – all* 17 583 750 −0.09 −0.15 −0.03 0.004 2.44 2.33 0.019
YMRS scores – plasma* 5 192 176 −0.09 −0.16 −0.01 0.017 2.96 2.47 0.013
YMRS scores – serum 10 247 421 −0.07 −0.15 0.00 0.052 1.63 1.18 0.235
Depression
Age of BD patients – all 14 346 702 0.01 −0.04 0.06 0.681 −1.41 −1.21 0.225
Age of controls – all 14 346 702 0.00 −0.06 0.07 0.996 −1.00 −0.76 0.445
Age difference(BD-HC) – all 14 346 702 0.08 −0.07 0.24 0.262 −1.22 −3.99 0.001
%Females (HC) – all 14 346 702 −0.00 −0.02 0.01 0.850 −1.03 −1.62 0.104
%Females (Patients) – all 14 346 702 0.00 −0.01 0.01 0.782 −1.28 −2.30 0.020
Difference in %females
(BD-HC) – all
14 346 702 0.02 −0.01 0.05 0.193 −0.95 −3.68 0.001
Mean illness duration
(years) – all*
5 103 359 −0.14 −0.20 −0.07 0.001 −2.47 3.44 0.001
Sample size – all 15 352 722 0.00 −0.00 0.01 0.070 −1.60 −3.74 0.001
Year of publication – all 15 352 722 0.03 −0.14 0.19 0.726 −61.80 −0.35 0.722
HDRS scores – all* 13 311 609 −0.23 −042 −0.04 0.018 4.40 1.93 0.053
HDRS scores – serum 11 274 427 −0.12 −0.35 0.09 0.265 1.70 0.60 0.542
Euthymia
Age of BD patients – all 24 1598 1459 −0.00 −0.02 0.02 0.950 0.11 0.23 0.831
Age of controls – all 24 1598 1459 −0.00 −0.02 0.01 0.802 0.16 0.36 0.712
Age difference(BD-HC) – all 24 1598 1459 0.02 −0.06 0.11 0.537 0.04 0.41 0.676
%Females (HC) – all 23 1425 1197 0.00 −0.01 0.01 0.878 −0.03 −0.05 0.995
%Females (Patients) – all 23 1425 1197 0.00 −0.01 0.02 0.690 −0.26 −0.40 0.684
Difference in %females
(BD-HC) – all
23 1425 1197 0.01 −0.02 0.03 0.555 0.06 0.68 0.495
Number of mood
episodes – all
5 206 220 0.01 −0.05 0.06 0.833 −0.24 −0.58 0.557
Illness duration (years) – all 13 831 696 0.01 −0.02 0.05 0.577 0.01 0.01 0.992
Illness duration (years) –
excluding Barbosa 2010,
2012, 2013
10 739 575 −0.01 −0.04 0.02 0.496 0.13 0.48 0.630
Sample size – all 24 1598 1459 −0.00 −0.01 0.01 0.530 0.12 0.85 0.390
HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale; CI, Confidence interval; BD, Bipolar disorder; HC, healthy controls; N/A, not applicable
*p<0.05
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When we carried out sub-group analyses according to
the use of psychiatric medication, we verified that BDNF
levels remained decreased with a moderate effect size
in subjects in mania when the subjects were drug-free
(g = −0.66, 95 % CI −1.14 to −0.10, P = 0.020, 6
between-group comparisons, n = 361) but not when the
subjects were on psychiatric medication (g = −0.54,
95 % CI −1.09 to −0.00, P = 0.051, 14 between-group
Fig. 1 Forest plots of between-group meta-analyses measuring peripheral brain-derived neurotrophic factor (BDNF) levels in subjects with bipolar
disorder compared to healthy controls, separated by mood state and medication status. (a) Mania, studies separated according use of medication.
(b) Depression, studies separated according use of medication. The sizes of the circles are proportional to the sample size. Circles depict individual
studies and diamonds depict the pooled effect sizes. Serum and plasma BDNF levels were decreased in subjects with bipolar disorder in mania
and depression on and off psychiatric medication when compared to healthy controls
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comparisons, n = 1,058). However, in the last sub-
group, the 95 % CI was large, and the result was ver-
ging on significant (Table 1, Fig. 1a). Similarly, BDNF
levels remained decreased with a large effect size in in-
dividuals in depression irrespective of them being drug-
free (g = −1.24, 95 % CI −1.88 to −0.61, P = 0.001, 3
between-group comparisons, n = 257) or on psychiatric
medication (g = −0.90, 95 % CI −1.59 to −0.55, P = 0.001,
13 between-group comparisons, n = 839; Table 1, Fig. 1b).
Peripheral BDNF levels were not significantly altered in
BD participants in a bipolar mixed episode compared to
healthy controls (g = 0.09, 95 % CI −0.57 to 0.75, P = 0.787,
3 between-group comparisons, n = 213); however, only
three studies [57, 72, 75] were included in this sub-group
and the 95 % CI was extremely large and, consequently,
this analysis is likely to be underpowered (Table 1,
Additional file 1: Figure S2).
We set to verify if there were differences in the extent
of the decrease of peripheral BDNF levels according to
mood states in order to assess the properties of periph-
eral BDNF levels as a possible state biomarker of disease
activity in BD. For this, we performed a direct comparison
of the ESs of the different studies in mania, depression,
and euthymia. In general, the median and interquartile
range of the ESs were different across the mood spectrum
(−0.67, −1.09 to 0.06 in mania; −0.86, −1.91 to −0.13 in de-
pression; −0.03, −0.24 to 0.31 in euthymia; P = 0.002, 58
comparisons, n = 5,528). Peripheral BDNF levels were
equally decreased in mania and depression (P = 0.340,
34 comparisons, n = 2,471), and both manic and de-
pressive states presented BDNF levels to be decreased
when compared to the euthymic state (P = 0.014, 43
comparisons, n = 4,454 for mania vs. euthymia; P = 0.001,
39 comparisons, n = 4,131 for depression vs. euthymia;
Bonferroni correction for multiple comparisons applied).
Although the difference between those in acute manic and
depressive episodes was statistically significant when com-
pared to those in euthymia, the variability was large, and
there was considerable overlap between the values of
BDNF levels found in mania and depression with those in
euthymia (Fig. 3a).
In univariable meta-regression models, we found a
negative relationship between BDNF levels and severity
of manic symptoms according to YMRS scores in per-
sons with acute mania, and of depressive symptoms ac-
cording to HDRS scores in persons with a current
Fig. 2 Forest plots of between-group meta-analysis measuring peripheral brain-derived neurotrophic factor (BDNF) levels in subjects with bipolar
disorder in euthymia compared to healthy controls. All studies referred to persons on psychiatric medication. The sizes of the circles are proportional to
the sample size. Circles depict individual studies and diamonds depict the pooled effect size. Serum and plasma BDNF levels were not altered in persons
with bipolar disorder in euthymia when compared to healthy controls
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depressive episode, indicating that the greater the se-
verity of manic and depressive symptoms, the greater
the decrease in BDNF levels (Table 1, Fig. 3b, c). When
a separate analysis according to the source of periph-
eral BDNF was performed, we verified that, in mania,
the severity of YMRS scores was negatively related to
the magnitude of the ES in plasma, but not in serum. In
depression, when we sub-grouped the meta-regressions
according to source, the previous significant effect was
lost in serum, and, since only two studies provided data
on HDRS in plasma of depressed individuals, it was not
possible to perform a meta-regression in this scenario.
However, this may suggest that most of the significance of
the association of HDRS scores with BDNF levels was due
to the use of plasma in the same line as that in mania
(Table 1).
Another important predetermined moderator was
length of illness, defined as the difference between age at
the moment of the blood draw and age of the occur-
rence of the first episode in years. In univariable meta-
analysis, we found a negative relationship between
BDNF levels and length of illness in years during a
depressive episode, but not during a manic episode.
Since most of the studies did not provide data on
length of the current index mood episode, it is not pos-
sible to analyse if the significant result found in depres-
sion was due to longer depressive episodes and a
consequent decrease in time spent in remission. During
euthymia, we found no relationship between length of
illness and BDNF levels, even when three studies con-
ducted by Barbosa et al. [43–45], which could be con-
sidered potentially outliers, were excluded (Fig. 3d,
Table 1).
BDNF levels increase after successful treatment of mania
In order to verify if pharmacological treatment of an
index mood episode induced changes in peripheral
BDNF levels, we conducted two within-group meta-
analyses of longitudinal studies, one of BDNF changes
before and after treatment of a manic episode, and one
of BDNF levels before and after treatment of a depres-
sive episode. In total, 18 studies were included [8, 47, 51,
55–57, 59, 61, 64, 65, 67, 71, 78, 84, 87–90]. Thirteen
studies referred to pharmacological treatment of a manic
Fig. 3 (a) Direct comparison of the effect sizes of the different studies in mania, depression, and euthymia. Peripheral brain-derived neurotrophic
factor (BDNF) levels were equally decreased in mania and depression (P = 0.340), and both manic and depressive states presented BDNF levels
decreased when compared to euthymic state (P = 0.002). (b) Meta-regression of the effect sizes of peripheral BDNF levels against severity of
mania as assessed by the Young Mania Rating Scale (YMRS) scores, showing more accentuated decreases in BDNF levels with increase in YMRS
scores (P = 0.004). (c) Meta-regression of the effect sizes of peripheral BDNF levels against severity of depression as assessed by the Hamilton
Depression Rating Scale (HDRS) scores, showing more accentuated decreases in BDNF levels with increase in HDRS scores (P= 0.018). (d) Meta-regression
of the effect sizes of peripheral BDNF levels against duration of illness in years in euthymic subjects, showing no association between BDNF levels and
duration of bipolar illness in years during euthymia (P= 0.577)
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Fig. 4 Forest plots of within-group meta-analyses measuring peripheral brain-derived neurotrophic factor (BDNF) levels in subjects with bipolar disorder
before and after treatment for an index acute manic or depressive mood episode. (a) Mania studies grouped according the source of the blood sample.
All studies presented response to the manic episode after pharmacological treatment, as defined as a decrease of at least 50 % on the Young Mania Rating
Scale scores. Plasma BDNF levels increased after successful treatment of an index manic episode. Serum BDNF levels remained unchanged. (b) Depression
studies grouped according the source of the blood sample. Serum and plasma BDNF levels remained unchanged after treatment of an index depressive
episode. (c) Depression studies grouped according response or non-response to pharmacological treatment of the acute depressive episode, defined as a
decrease of at least 50 % on the Hamilton Depression Rating Scale scores. Serum and plasma BDNF levels remained unchanged after treatment of an index
depressive episode regardless of response or non-response to treatment. The sizes of the circles are proportional to the sample size. Circles
depict individual studies and diamonds depict the pooled effect sizes
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episode [8, 47, 51, 55, 57, 59, 61, 64, 65, 84, 87, 88, 90],
comprising 556 subjects. In all studies, response, defined
as a decrease in at least 50 % of the baseline mean
YMRS scores, was achieved in all studies, and full remis-
sion, defined as mean YMRS scores of less than 7 at
follow-up, was achieved in all but three [51, 65, 88].
Overall, peripheral BDNF levels showed a small increase
after treatment of a manic episode (g = 0.26, 95 % CI
0.09 to 0. 54, P = 0.003, 13 between-group comparisons,
n = 556). When performing sub-group analyses
according to source, we verified that BDNF levels in-
creased in plasma (g = 0.23, 95 % CI 0.02 to 0.44, P =
0.028, 7 between-group comparisons, n = 332) but not in
serum (g = 0.39, 95 % CI −0.03 to 0.81, P = 0.065, 5
between-group comparisons, n = 122; Fig. 4a, Table 2).
One study assessed BDNF in whole blood [64] and
found a non-significant result. In univariable meta-
regressions, we found no influence of duration of follow-
up in weeks or of improvement of YMRS scores in the
ES of BDNF levels before and after treatment (Table 2).
Table 2 Statistics on within-group meta-analyses regarding peripheral brain-derived neurotrophic factor levels in bipolar disorder
Within-Group N of pairwise Number of subjects Meta-analysis Heterogeneity
Hedges’ g 95 % CI P value I2 Q P value
Mania
Mania– all* 13 556 0.26 0.09 0.45 0.003 69.69 39.60 0.001
Serum and plasma* 12 454 0.30 0.08 0.44 0.005 78.48 18.59 0.001
Serum 5 122 0.39 −0.03 0.81 0.065 78.48 18.59 0.001
Plasma* 7 332 0.23 0.02 0.44 0.028 55.20 13.39 0.037
Whole blood 1 102 0.01 −0.19 0.20 0.941 N/A N/A N/A
Depression
Depression – all 8 184 0.05 −0.28 0.38 0.747 76.51 29.79 0.001
Depression – except Mackin 2007 [71] 7 164 0.15 −0.18 0.49 0.364 72.84 22.09 0.001
Serum 5 88 −0.12 −0.52 0.29 0.563 72.15 14.36 0.006
Plasma 3 96 0.40 −0.40 1.21 0.329 85.93 14.22 0.001
Response 3 115 −0.06 −0.24 0.18 0.492 N/A N/A N/A
Non-response 5 69 0.13 −0.53 0.79 0.702 85.69 1.51 0.001
Moderators within-group N of pairwise Number of subjects Meta-regression Meta-regression
Slope 95 % CI P value Intercept Z P value
Mania
Age of BD Patients – all 9 456 −0.01 −0.04 0.02 0.398 0.80 1.39 0.165
% Females – all 13 556 0.01 −0.03 0.02 0.478 0.07 0.27 0.782
Baseline YMRS scores 12 542 0.01 −0.01 0.02 0.930 0.20 0.63 0.522
Difference in YMRS(After – Before) 12 542 −0.01 −0.02 0.02 0.298 0.16 1.42 0.155
% Change in YMRS Scores 12 542 −0.01 −0.02 0.01 0.213 0.77 1.73 0.083
Follow-up duration (weeks) 13 556 0.01 −0.01 0.03 0.396 0.19 1.63 0.101
Year of publication 13 556 −0.07 −0.12 −0.01 0.011 141.63 2.53 0.011
Depression
Age of BD patients – all 6 164 −0.01 −0.05 0.02 0.393 0.50 0.69 0.489
% Females – all* 6 164 0.01 0.00 0.02 0.042 −0.54 −2.29 0.021
% Females – excluding Mackin 2007 [71] 5 144 0.01 −0.01 0.01 0.555 −0.20 −0.68 0.490
Baseline HDRS scores 8 184 0.02 −0.18 0.22 0.823 −0.42 −0.19 0.845
Difference in HDRS(After – Before) 7 164 −0.02 −0.09 0.06 0.658 −0.01 −0.01 0.988
% Change in HDRS scores 7 164 0.01 −0.01 0.02 0.566 −0.05 −0.13 0.892
Follow-up duration (weeks) 8 184 0.01 −0.05 0.07 0.673 −0.04 −0.12 0.899
Year of publication 8 184 0.01 −0.11 0.11 0.987 −1.76 −0.01 0.988
HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale; CI, Confidence interval; BD, Bipolar disorder; N/A, Not applicable
*p<0.05
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Seven studies [56, 57, 67, 71, 78, 89, 90] comprising
184 subjects investigated changes in peripheral BDNF
levels before and after treatment for a current depressive
episode. Overall, there were no changes in peripheral
BDNF levels before and after pharmacological treatment
(g = 0.06, 95 % CI −0.29 to 0.41, P = 0.747, 8 between-
group comparisons, n = 184). When we excluded the
study of Mackin et al. [71], which employed mifepristone
as the pharmacological treatment for depression, the
results remained unchanged (Table 1). In addition, the
results remained non-significant when we sub-grouped
the studies conducted using serum or plasma separ-
ately (Fig. 4b), and according to presence or absence of
response to treatment of the depressive episode as
assessed using HDRS scores (Fig. 4c). Again, the meta-
regressions showed no effect of length of the treatment
employed in weeks and changes of HDRS scores on
BDNF levels (Table 2).
Investigation of heterogeneity: sub-groups and
meta-regressions analyses
We performed further sub-group and meta-regression
analyses to explore potential sources of between-study
heterogeneity in both between- and within-group meta-
analyses. In the between-group meta-analyses, the re-
sults remained significant in depression when we
assessed peripheral BDNF levels according to source (i.e.
serum or plasma), and also remained non-significant in
euthymia regardless of the source. However, in mania,
the results remained significant in serum (g = −0.97,
95 % CI −1.41 to −0. 53, P = 0.001, 12 between-group
comparisons, n = 800) but not in plasma (g = −0.03, 95 %
CI −0.98 to 0.95, P = 0.951, 6 between-group compari-
sons, n = 394). However, in plasma, only six studies were
available, and the 95 % CI were extremely large. When
we analysed studies in mania using plasma excluding the
studies of Barbosa et al. [43, 44], which included chronic
and heavily medicated subjects and were possible out-
liers, the pooled ES yielded a significant result (g = −0.72,
95 % CI −1.27 to −0.17, P = 0.001, 4 between-group
comparisons, n = 116).
Again, when we performed sub-group analyses consid-
ering whether the control group was matched to the bi-
polar group, we found no differences between matched
and non-matched studies in depression and euthymia.
However, in mania, BDNF levels only remained significant
in the non-matched subgroup, although again the 95 % CI
was very large (g = −0.46, 95 % CI −0.99 to 0.07, P = 0.073,
14 between-group comparisons, n = 1,039 in the matched
group; g = −0.84, 95 % CI −1.51 to −0.18, P = 0.042, 14
between-group comparisons, n = 358 in the not-matched
group). In addition, we wanted to verify if there were dif-
ferences in peripheral BDNF levels in those with types I or
II BD. In euthymia, the differences in BDNF levels
between persons with BD and healthy controls remained
non-significant regardless of whether the subjects had type
I or II BD. In depression, the results remained significant
only when depressed subjects with type I BD were in-
cluded (g = −1.27, 95 % CI −1.80 to −0.72, P = 0.001, 12
between-group comparisons, n = 588). It was not possible
to carry out an analysis considering only subjects in a de-
pressive state with type II BD. Heterogeneity remained
very high in all sub-group scenarios (Table 1).
In the meta-regressions of the between-group meta-
analyses, sex, year of publication, and sample size did
not seem to contribute to heterogeneity in between-
group meta-analyses comparing peripheral BDNF levels
of participants in mania, depression, or euthymia com-
pared to their respective healthy controls (Table 1). The
mean age of manic subjects, and most notably the mean
difference in age between manic subjects and healthy
controls included in a particular study appeared to con-
tribute to heterogeneity in the between-group meta-
analysis of mania versus healthy controls. Mean age did
not seem to contribute to heterogeneity in between-
group meta-analyses comparing peripheral BDNF levels
of participants in depression or euthymia compared to
their respective healthy controls (Table 1).
In the within-group meta-analysis involving partici-
pants with a manic or depressive state, sub-group ana-
lyses or meta-regression could not explain the high
heterogeneity that was found. In the within-group meta-
analysis of mania, when we performed sub-group ana-
lyses according to the source of BDNF, we verified that
studies that assessed BDNF in plasma showed lower het-
erogeneity than those in serum (I2, 55.2 in plasma and
78.5 in serum; Table 2). When we assessed the effect of
moderators using meta-regressions, we verified that
heterogeneity in mania could not be explained by per-
centage of female participants, mean age, mean length
of illness, follow-up time, sample size, or differences in
YMRS scores between baseline and post-intervention
(Table 2). Year of publication was the only moderator
that achieved statistical significance in the treatment of
a manic episode, showing that the magnitude of the ES
decreased with time (Table 2). In depression, higher
percentages of female participants were associated with
a small increase in BDNF levels (Table 2).
Sensitivity analyses and cumulative meta-analyses
We conducted a sensitivity analysis in all meta-analyses
excluding studies one at a time to determine the robust-
ness of the analyses and to verify if a particular study
was responsible for the high heterogeneity or signifi-
cance of the pooled ES estimate. No single study thor-
oughly explained the heterogeneity, and the results
remained significant in all cross-sectional meta-analysis
of mania, depression, euthymia, and all longitudinal
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meta-analysis of mania and depression (Additional file 1:
Figures S3 to S7).
We sought to determine the stability of ES estimates
over time through cumulative meta-analyses. For the
between-group meta-analysis that included participants
with mania versus healthy controls, the ES estimates were
larger from 2005 to 2013. Thereafter, the ES reached sta-
bility (Additional file 1: Figure S8). An opposite behaviour
was found for the between-group meta-analysis of depres-
sion versus healthy controls, where the magnitude of the
pooled ES increased from 2006 to 2010, and thereafter
started to decrease again, reaching stability in 2013
(Additional file 1: Figure S9). For the between-group
meta-analysis of euthymic BD versus healthy controls, a
small dispersion in the ES from 2006 to 2011 was veri-
fied, while the ES of individual studies reached stability
since then (Additional file 1: Figure S10). When considering
the within-group meta-analyses of both depression and
mania, ES estimates reached stability since 2013, becoming
smaller and tending towards zero (Additional file 1: Figures
S11 and S12).
Bias assessment and power
The evidence suggests the existence of small study ef-
fects, which is indicative of publication bias, in the
between-group meta-analyses comparing depression
or mania to healthy controls (Additional file 2: Tables
S4 and S5), whereas evidence for publication bias was
not observed in the other meta-analyses. Funnel plots
are depicted in Additional file 1: Figures S13 to S17.
The trim-and-fill procedure was thus performed in the
between-group meta-analyses of depression or mania
compared to healthy controls. However, no additional
studies were imputed in these meta-analyses (Additional
file 1: Figures S13 and S14). In addition, the fail-safe N
statistic revealed that 253 and 409 additional studies,
respectively, would be required to turn the ESs of the
between-group meta-analyses of mania and bipolar de-
pression non-significant.
An excess of significance bias was assessed in all meta-
analyses through the Ioannidis test [40], considering the
ES of the largest study as the true ES of each meta-
analysis. An excess of significance bias was observed for
between-group meta-analyses that included participants
with euthymic BD and mania compared to healthy con-
trols, and for the within-group meta-analysis of depres-
sion (Additional file 2: Table S5). No evidence for this
type of bias was found in the between-group meta-
analysis of depression versus healthy controls, or in the
between-group meta-analysis of serum BDNF differences
in manic subjects versus controls. There was also no evi-
dence of excess significance in the within-group meta-
analysis that included participants with mania (Additional
file 2: Table S5).
Between-study heterogeneity was large or very large
for all meta-analyses, and the 95 % prediction intervals
of all meta-analyses included the null value, meaning
that if a new future study were conducted on the subject,
it could generate a non-significant result (Additional file 2:
Table S5).
In addition, we estimated the sample size required to
identify an ES of 0.26 (we assumed that the true real ES
would equal that of the pooled ES of our meta-analysis)
taking in account a power of 0.80 and an alpha level of
0.05 (two-tailed paired t-test) following treatment of
acute mania. These calculations estimated that a sample
size of 119 manic participants would be necessary. Eli-
gible study sample sizes ranged from 10 to 116 partici-
pants, and thus were likely underpowered to detect
differences in BDNF under these assumptions. In the
between-group meta-analyses, 11 participants were ne-
cessary to reliably detect the observed ES in depression,
while 28 participants were needed to detect the observed
difference in mania.
Discussion
Our six meta-analyses of peripheral BDNF levels in BD
included a total of 52 cross-sectional or longitudinal
studies comprising 6,481 participants. BDNF levels were
moderately decreased in persons with BD during mania
and largely decreased during depression. The extent of
the decrease in peripheral BDNF levels paralleled the se-
verity of manic and depressive episodes [14]. There were
no alterations in peripheral BDNF levels in euthymia or
in mixed states compared to healthy controls. Notably,
there was no association between BDNF levels and dur-
ation of illness in euthymia, suggesting it is not a useful
biomarker of stage. Importantly, in direct comparisons
across distinct mood states, we demonstrated that the
magnitude of the reduction in peripheral BDNF levels is
comparable in mania and depression, and that both are
equally reduced when compared to euthymia, suggesting
peripheral BDNF levels as a biomarker capable of ad-
dressing the matter of disease activity in BD. Addition-
ally, peripheral BDNF levels increased after a successful
treatment of an index manic episode but not of a de-
pressive episode – although it should be noted that, in
general, treatments for mania are more robustly effica-
cious than for depression. Insufficient data were avail-
able to clarify whether it is a biomarker of treatment
response or prognosis.
Lower levels of peripheral BDNF levels in manic and
depressive episodes of BD were found in previous meta-
analysis on the topic [14–16, 25, 26]. The first three
published found BDNF levels decreased in both mania
and depression, with normal levels in euthymia [14–16].
More recently, two published meta-analysis suggested
decreased levels of peripheral BDNF in bipolar
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depression but not in mania [25, 26]; however, one [26]
had very strict inclusion criteria, and did find BDNF
levels decreased in mania after the exclusion of one
study which was an outlier [44]. The second one, the
most recently published, also did not pinpoint decreased
levels of peripheral BDNF in mania; however, it did so in
serum when a sub-group analysis was executed. They
also found strong evidence of publication bias, with the
trim-and-fill estimation suggesting the presence of sev-
eral missing reports, and the authors proposed that the
studies and the literature that suggest that the finding
that BDNF levels are decreased in acute episodes of BD
might possibly be unreliable due to the presence of pub-
lication bias and bias in the individual included studies.
However, this later study had an incomplete systematic
search and the possible introduction of metabias (bias
inserted in a meta-analysis due to issues in the system-
atic review) – confounding interpretation of this meta-
analysis. Although the previous study discussed herein
[25] and the present one had very similar inclusion and
exclusion criteria, and considered studies published in a
similar period of time, we were able to include almost
50 % more studies and almost twice the number of par-
ticipants (35 vs. 52 studies, and 3,798 vs. 6,481 individual
participants, in the study of Munkholm et al. [25] and in
the present study, respectively). Contrary to the results
of Munkholm et al. [25], the trim-and-fill method did
not suggest any missing studies in the between-group
meta-analyses. This conceivably suggests that the dis-
cordance between our findings and those of Munkholm
et al. [25] may rest on differences in systematic search
strategy. Therefore, our results regarding decreased per-
ipheral BDNF levels in mania are arguably a more accur-
ate portrait of the reality than the null results depicted
by Munkholm et al. [25].
Peripheral BDNF as a biomarker in BD
The role of BDNF in serum and plasma as a biomarker
in psychiatric conditions, including BD, has been re-
cently debated. We found a negative association between
serum and plasma BDNF levels and severity of manic
and depressive symptoms in mania and depression,
meaning that the higher the severity of manic or depres-
sive symptoms, the lower the BDNF levels. This is in line
with a recent meta-analysis conducted by Molendijk et al.
[91], which also found a negative association with serum
BDNF levels and severity of depressive symptoms in drug-
free subjects with major depressive disorder. In 2010, we
first proposed the measurement of proteins in peripheral
blood as a laboratory tool to acquire insight into illness
activity, and put forward the idea of peripheral BDNF
levels as a biomarker of disease activity in BD [17]. In
that preliminary report we found that serum BDNF
levels in BD were capable of discriminating subjects in
mania from subjects in euthymia and healthy controls
with a moderate accuracy of 0.72, and also subjects in
depression from subjects in euthymia and healthy con-
trols, again with a moderate accuracy of 0.76 [17]. Sub-
sequently, we investigated if peripheral BDNF levels
were decreased to the same extent during acute mood
episodes across the schizoaffective spectrum [16], and
uncovered that serum and plasma BDNF levels are
equally decreased during acute mood episodes of BD
and major depressive disorder, and in schizophrenia,
and that its levels were normal in BD during euthymia
and in major depressive disorder during remission. We
confirmed our previous findings in the present study,
showing that peripheral BDNF levels diminished simi-
larly in both manic and depressive episodes of BD and
were normal in euthymia, and extended our findings by
also showing that BDNF levels are decreased in tandem
with severity of symptoms. However, the variability and
consequent overlap among the results found in acute
episodes with those in euthymia were large, thereby
preventing its use in isolation in clinical practice as a
useful laboratory blood biomarker. This is somehow
reflected by the only moderate discriminatory accuracy
properties that we described in our earlier findings [17].
In keeping with this view, peripheral BDNF levels hold
promise as a biomarker of disease activity in BD, pos-
sibly as a component of a panel of several proteins
[17]. This approach has also been proposed by others
[92, 93], although it has been applied to genomics and
not to blood protein content.
Recently, using meta-analytic techniques, we established
that peripheral BDNF levels are decreased in schizophre-
nia [94] and in major depressive disorder [91], and that
the extent of the decrease is indistinguishable among
acute mood states and schizophrenia along the schizoaf-
fective continuum [16]. The ability of a biomarker to use-
fully support clinical diagnosis in psychiatry would be of
great significance [9, 14, 16, 95]. Considering the schizoaf-
fective spectrum, the most valuable diagnostic biomarkers
would be those capable of truly differentiating bipolar
from unipolar depression and mania from acute schizo-
phrenia [9] – seemingly different pathologies with over-
lapping symptoms. In 2009, based on preliminary results,
we proposed serum BDNF levels as a possible adjunctive
tool to discriminate between bipolar and unipolar depres-
sion with a high accuracy of 0.95 [9]. However, based on
the present data, and on our subsequent meta-analyses on
peripheral BDNF in schizophrenia and in major depressive
disorder [16, 91, 94], it seems clear that peripheral BDNF
levels are not useful as a diagnostic biomarker in psychi-
atric disorders because of lack of specificity.
In addition to the above, peripheral BDNF has also
been suggested as a stage biomarker in psychiatry, cap-
able of capturing the neuroprogressive nature of BD
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[11]. The neuroprogression hypothesis postulates that
the central nervous system pathologically reorganizes
during the course of severe mental illness, resulting in al-
terations that persist even during euthymia [96], and this
notion is the core idea supporting the conceptualization
of a staging model in BD [97, 98]. Decreased serum BDNF
levels were found in the late stages of BD when compared
to earlier stages (i.e. more than 10 years and less than
3 years after disease onset, respectively) [62], and a re-
analysis of this data proposed that serum BDNF levels are
capable of differentiating late stages from early stages with
a sensitivity of 100 %, a specificity of 89 %, and an overall
accuracy of 0.95 [11]. However, in this study, the subjects
in the later stage presented with HDRS scores of 9.2
against 3.8 in the early stages, and provided no data re-
garding for how long the subjects were in euthymia. This
raises the possibility that the decreased serum BDNF
levels found in late-stage BD may be an artefact of more
severe depressive symptoms, as well as the possibility of
being a ‘scar’ of a depressive episode [99]. In our present
study, we found absolutely no association between length
of illness or age and peripheral BDNF levels in euthymia,
suggesting that BDNF does not have value as a biomarker
of stage. These findings are in contrast to what is seen in
schizophrenia, where there is evidence of a decrease in
BDNF levels with age and length of illness [94]. This line
of reasoning is also in accordance with a recent study that
found normal BDNF levels in the late stage of BD [74]. In
addition, there is no correlation between cognition – a
domain considered with neuroimaging changes to be a
nucleus of allostatic load and the staging model [100] –
and peripheral BDNF levels in euthymia [53]. Also,
there were no differences in BDNF levels between BD
types I and II in euthymia. It is also conceivable that
peripheral BDNF levels might only be altered in a sub-
group with a more detrimental long BD course, but either
way, our current data do not support the measurement of
peripheral BDNF levels as a biomarker of staging in BD.
The neurotrophin hypothesis of BD
Scientists have debated the temporal relationship and the
consequent matter of causality concerning alterations in
BDNF levels and changes in mood states in BD. It remains
unclear whether a decrease in peripheral BDNF levels or
the initiation of a mood episode materializes first, and
whether an increase in peripheral BDNF levels or the re-
covery from a mood episode occurs first, or even if
changes in BDNF levels and symptoms happen concomi-
tantly. While the temporal behaviour of peripheral BDNF
levels preceding a mood episode remains largely un-
known, there are far more data regarding its changes after
the treatment of an index mood episode. In our longitu-
dinal meta-analyses, we were able to show that peripheral
BDNF levels increase following the successful treatment
of an index manic episode. Moreover, we suggested that
BDNF levels increase in plasma but not in serum, al-
though not proportionally to the severity of manic
symptoms as assessed by the YMRS scores, meaning
that, if remission is achieved, BDNF levels increase, no
matter how severe the manic episode previously was.
The fact that plasma BDNF levels increased with an ES
of 0.23 with achieving euthymia, while the ES of plasma
BDNF levels was −0.72, might suggest that BDNF levels
keep increasing after improvement of manic symptoms.
Still, we cannot draw any definitive causal association
in the matter. In sharp contrast to the increased plasma
BDNF levels found with treatment of a manic episode,
no increase in peripheral BDNF levels were found after
treatment of a depressive episode, regardless of whether
it was plasma or serum, and regardless of the presence,
or not, of response to treatment. However, it is important
to point here that response to treatment in depression was
mostly incomplete, with subjects in most studies still pre-
senting depressive symptoms at follow-up.
If one considers this line of reasoning correct, then it
is tempting to speculate that decreased levels of BDNF
in BD may very well represent an epiphenomenon, with-
out implying causality; in support of this is the fact that
the polymorphisms of the BDNF gene are not associated
with BD [101] or with hippocampal volumes in neuro-
psychiatric disorders [102]. Most importantly, BDNF
levels are ubiquitously decreased across diverse psychi-
atric pathologies [16, 91, 94], and decreased in both
poles of BD – mania and depression – when one would
possibly expect opposite behaviours if its levels were
causally related to the development of a mood episode.
Either way, our results suggest that the neurotrophin
pathway is altered in BD, and provide further evidence
supporting the neurotrophic hypothesis in mood disor-
ders. In addition, notwithstanding evidence that indi-
cates that peripheral levels of BDNF may reflect BDNF
activity in the brain [103, 104], it remains unproved
whether peripheral BDNF levels would proxy brain
levels of this protein.
Strengths and limitations
Our study relied on a large sample size (52 studies with
6,481 subjects), which permitted us to draw conclusions
through meta-analyses and meta-regression techniques.
Our positive results are unlikely to be substantially influ-
enced by publication bias, since the funnel plots in all
cases were symmetrical, the trim-and-fill procedure did
not point to any missing study necessary to impute in
order to ‘correct’ the ES, and in general there were no
associations between the magnitude of the pooled ESs
and year of publication; however, this cannot be com-
pletely excluded in mania, since the presence of an ex-
cess of positive (i.e. statistically significant) published
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studies was suggested by the Ioannidis test. However,
the Ioannidis test of excess of significance relies on the
assumption that the ‘true’ ES is that of the largest study,
and this premise may be threatened when the largest
study included is not particularly large or well-conducted,
and when there is significant heterogeneity. In both sce-
narios, the test of excess of significance can falsely signal
bias, when in truth what is being pointed out is genuine
heterogeneity due to real differences among the different
studies among dissimilar populations. Since the largest re-
port included in our meta-analyses included 196 subjects
and, in general, there were ample differences in the demo-
graphic characteristics of the studies included, this possi-
bility cannot be discarded. In addition, through a series of
sensitivity and sub-group analyses, we were able to rule
out the possibility that the results were biased due to a
unique outlier. The abovementioned approach also
allowed us to investigate and rule out any single study
as the sole source of the high heterogeneity found in
virtually all analyses.
Notwithstanding its strengths, our paper has some in-
herent limitations due to its design and statistical methods
employed. First, meta-analyses are retrospective in nature,
affected by the methodological rigour of the studies in-
cluded, comprehensiveness of search strategies, and pos-
sible publication bias. We tried to keep the probability of
bias to a minimum by doing a thorough search for data
and by using explicit criteria for study selection, data col-
lection, and data analysis. We did not restrict the studies
included to those in English, and included not only pub-
lished articles, but conference proceedings as well, there-
fore, avoiding missing negative results. This allowed us to
conduct the most comprehensive meta-analysis on the
topic so far. We believe that using this approach, the re-
sults and conclusions can provide reliable information.
Second, some of the sub-groups and meta-regression ana-
lyses may have failed to achieve statistical significance due
to a lack of power in these specific analyses, giving a po-
tentially false negative result. This may have been the rea-
son for the lack of significance of decreased BDNF levels
in medicated persons in a manic episode when compared
to controls, in mania compared to matched controls by
age and sex, and of the association between YMRS and
serum BDNF levels. Third, the meta-analysis of BDNF
levels in persons with BD compared to controls provides
us with a pooled result originating from cross-sectional
studies. Therefore, we cannot draw any causal associa-
tions. Thus, we do not know if a decrease in peripheral
BDNF levels is a cause and pre-requisite for the occur-
rence of an index mood episode or an allostatic counter-
balancing mechanism as a consequence of the occurrence
of the mood episode. It is also not possible to infer if per-
ipheral BDNF levels decrease before, concomitantly, or
after euthymia is successfully achieved. Fourth, virtually
no study included data on length of the acute mood epi-
sode, which would be a potentially crucial moderator, if
one considers the prospect of peripheral BDNF levels fur-
ther decreasing during the course of an unmedicated
acute mood episode. This appears to be the case in schizo-
phrenia, where a more accentuated decrease in BDNF is
present with longer untreated psychosis [105]. Fifth, in
our meta-analyses of changes in BDNF levels with treat-
ment for acute mania or depression, we considered the
studies as responders or non-responders using the mean
values of the YMRS or HDRS scores of each study, and
not of individual subjects, with the exception of the study
of Rybakowski et al. [78], which provided data for re-
sponders and non-responders separately. This may specif-
ically have been an issue in the meta-analysis regarding
treatment of depression, where probably the sample of
each study has more variability in response than in the
mania studies. It should also be noted that, in depression,
the greatest mean response rate was 65 %, that none
achieved remission, and that in all studies, subjects had at
least residual manifestations of depression. Consequently,
the absence of an increase in BDNF levels after treatment
of a depressive episode may indicate an absence of sub-
stantial improvement. In addition, there was a manifold of
distinct medications employed in the therapeutics of the
depressive episodes, ranging from quetiapine, an approved
medication for this condition, to valproate, ketamine and
mifepristone, which can be considered experimental in
this situation. Sixth, we used length of illness as a proxy
for stage. Finally, as in other meta-analyses, our results
should be interpreted with caution because individual
studies varied greatly with respect to the demographic
characteristics and ethnicity of participants, type of psy-
chiatric medication on use, and duration of follow-up in
the within-group meta-analyses.
Future research
The temporal changes in BDNF levels in relation to a
mood episode remains one of the known unknowns of
science. Peripheral BDNF level changes in relation to the
occurrence of a mood episode could theoretically follow
three different patterns. First, peripheral BDNF could de-
crease before the beginning of a mood episode, which
would make BDNF a possible predictor of a future mood
episode; second, BDNF levels could decrease concomi-
tantly with a mood episode, turning BDNF into a bio-
marker of disease activity; and finally, peripheral BDNF
levels could decrease after the beginning of a mood epi-
sode. In this case, BDNF changes would be a conse-
quence of a mood episode, and its assessment could be
useful perhaps as a surrogate biomarker. To provide a
definitive answer to these questions a longitudinal study
with frequent blood draws would be necessary, with a
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within-subject design that also reduces noise and conse-
quently is less prone to bias. It is also true that a bio-
marker may be capable of measuring a variety of
clinical endpoints simultaneously.
One potentially interesting application of peripheral
BDNF levels is as a biomarker for predicting response to
treatment in an index mood episode. It would be of
great value to determine if baseline levels of peripheral
BDNF can predict response to treatment, differing be-
tween those who achieve remission and identifying those
who will be refractory. This is a simple analysis that can
be easily performed; however, it has been overlooked in
almost all studies. Data on this regard is scant and the
field would benefit from such investigation.
There is evidence from our present study that BDNF
levels can vary according to its source, meaning plasma
or serum. For instance, we found an association in the
meta-regressions between severity of manic and depres-
sive episodes, mostly in plasma, and in the within-group
meta-analysis BDNF increased after treatment of a
manic episode in plasma, but not in serum. We previ-
ously described a similar pattern in schizophrenia, with
antipsychotics increasing BDNF levels only in plasma
[94]. At the moment, most of the BDNF enquiries in BD
have used serum, with far less studies conducted in
plasma. However, serum and plasma represent, in fact,
two different compartments. This is highlighted by the
fact that BDNF concentrations in serum are 20- to 50-
times higher than in plasma [106]. Peripheral BDNF is
largely stored in platelets, which actively absorb it from
the circulation, and is released from activated platelets
in serum during the clotting process, and consequently
serum BDNF levels largely reflect the pool of BDNF
stored and released from platelets during coagulation
[107]. However, after being produced by the brain and
released into the circulation, BDNF has a half-life of less
than 10 minutes in the blood and is rapidly cleared from
the circulation mostly by the liver, in contrast to a plate-
let’s life-span of 9–11 days [108]. This logically implies
that plasma BDNF levels may be a more accurate marker
of acute changes in the central nervous system than
serum BDNF. This may be because of the fact that the
still ongoing release of BDNF from platelets obscures
serum BDNF levels, with ‘old’ BDNF actually being mea-
sured. We therefore suggest that future research should
preferentially consider plasma when assessing the BDNF
as a potential clinical biomarker. We could trace a paral-
lel with diabetes, where plasma would behave as fasting
glycaemia, representing acute changes in glycaemia, and
serum as glycated haemoglobin, representing a general
picture of glycaemia in the last 90 days. Since the life-
span of platelets is 10 days, serum BDNF levels would
better represent the general behaviour of BDNF in last
10 days, and plasma would represent acute changes in
BDNF. Finally, in our analyses, we uncovered that studies
with an ‘imperfect’ pairing of the control group regarding
age and sex may be more susceptible to bias, particularly
with differences in age. Lack of matching increases noise
and unduly distorts data. This is a concern not only for
studies on BDNF levels, but for all studies investigating
biomarker properties. We suggest that future study design
should take this into consideration.
Conclusions
Our meta-analyses of 52 cross-sectional or longitudinal
studies comprising 6,481 persons with BD and healthy
controls provide evidence that peripheral BDNF levels
are equally decreased in BD during the occurrence of
manic and depressive episodes, and that its levels appear
normal in euthymia. The extent of the decrease in per-
ipheral BDNF levels paralleled the severity of manic and
depressive symptoms, providing further evidence of per-
ipheral BDNF as a state-marker and consequentially as a
biomarker of disease activity for acute mood episodes of
BD. Our study also provides further evidence of the
neurotrophic hypothesis of BD, and solidifies the notion
of BD as a systemic disorder with peripheral manifesta-
tions. In summary, peripheral BDNF level, better docu-
mented in plasma than in serum, is a potential
biomarker of disease activity in BD. We propose that
peripheral BDNF may have a clinical application as a
part of a laboratory blood protein composite measure to
assess disease activity in BD.
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